TY - JOUR KW - ENL KW - T1R KW - biomarkers KW - correlates KW - leprosy KW - leprosy reactions AU - Luo Y AU - Kiriya M AU - Tanigawa K AU - Kawashima A AU - Nakamura Y AU - Ishii N AU - Suzuki K AB -

Leprosy reactions are acute inflammatory episodes that complicate the course of a infection and are the major cause of leprosy-associated pathology. Two types of leprosy reactions with relatively distinct pathogenesis and clinical features can occur: type 1 reaction, also known as reversal reaction, and type 2 reaction, also known as erythema nodosum leprosum. These acute nerve-destructive immune exacerbations often cause irreversible disabilities and deformities, especially when diagnosis is delayed. However, there is no diagnostic test to detect or predict leprosy reactions before the onset of clinical symptoms. Identification of biomarkers for leprosy reactions, which impede the development of symptoms or correlate with early-onset, will allow precise diagnosis and timely interventions to greatly improve the patients' quality of life. Here, we review the progress of research aimed at identifying biomarkers for leprosy reactions, including its correlation with not only immunity but also genetics, transcripts, and metabolites, providing an understanding of the immune dysfunction and inflammation that underly the pathogenesis of leprosy reactions. Nevertheless, no biomarkers that can reliably predict the subsequent occurrence of leprosy reactions from non-reactional patients and distinguish type I reaction from type II have yet been found.

BT - Frontiers in medicine C1 -

https://www.ncbi.nlm.nih.gov/pubmed/34746168

DA - 01/2021 DO - 10.3389/fmed.2021.694376 J2 - Front Med (Lausanne) LA - eng N2 -

Leprosy reactions are acute inflammatory episodes that complicate the course of a infection and are the major cause of leprosy-associated pathology. Two types of leprosy reactions with relatively distinct pathogenesis and clinical features can occur: type 1 reaction, also known as reversal reaction, and type 2 reaction, also known as erythema nodosum leprosum. These acute nerve-destructive immune exacerbations often cause irreversible disabilities and deformities, especially when diagnosis is delayed. However, there is no diagnostic test to detect or predict leprosy reactions before the onset of clinical symptoms. Identification of biomarkers for leprosy reactions, which impede the development of symptoms or correlate with early-onset, will allow precise diagnosis and timely interventions to greatly improve the patients' quality of life. Here, we review the progress of research aimed at identifying biomarkers for leprosy reactions, including its correlation with not only immunity but also genetics, transcripts, and metabolites, providing an understanding of the immune dysfunction and inflammation that underly the pathogenesis of leprosy reactions. Nevertheless, no biomarkers that can reliably predict the subsequent occurrence of leprosy reactions from non-reactional patients and distinguish type I reaction from type II have yet been found.

PY - 2021 EP - 694376 T2 - Frontiers in medicine TI - Host-Related Laboratory Parameters for Leprosy Reactions. UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568883/pdf/fmed-08-694376.pdf VL - 8 SN - 2296-858X ER -